跳转至内容
Merck
  • The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.

Expert opinion on investigational drugs (2007-12-22)
Mark J McKeage
摘要

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer. Complementary modes of action, a lack of pharmacokinetic interaction and distinct adverse effect profiles provide a strong rationale for combining these anticancer agents. In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Further clinical evaluation of this combination in this patient population is warranted.

材料
货号
品牌
产品描述

Sigma-Aldrich
DMXAA, ≥98% (HPLC), solid